Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | NAAA | Q02083 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CTSV | O60911 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310817 | 0.76 | CTSV (0.39) | ALDH1A1NAAAGRM2IDO1CTSV | |
| SCHEMBL24168933 | 0.75 | LMNA (0.41) | ALDH1A1TSHRIDO1CTSVCTSL | |
| SCHEMBL14817052 | 0.75 | LMNA (0.41) | ALDH1A1TSHRIDO1CTSVCTSL | |
| SCHEMBL3300637 | 0.75 | LMNA (0.41) | ALDH1A1TSHRIDO1CTSVCTSL | |
| SCHEMBL9911195 | 0.69 | IDO1 (0.33) | ALDH1A1NAAATSHRIDO1 | |
| SCHEMBL13998794 | 0.69 | BCHE (0.32) | ALDH1A1TSHR | |
| SCHEMBL10919889 | 0.68 | SMN1; SMN2 (0.33) | TSHR | |
| SCHEMBL11997771 | 0.68 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13645046 | 0.66 | — | — | |
| SCHEMBL10120664 | 0.66 | NAAA (0.43) | NAAAIDO1CTSVCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | ALDH1A1 873/4885NAAA 945/4885TSHR 2919/4885 |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, CDA | ALDH1A1 755/4885NAAA 927/4885TSHR 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.